[1] JOYCE J A, FEARON D T. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, 348(6230):74-80.
[2] SPILL F, REYNOLDS D S, KAMM R D, et al. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotech, 2016, 40: 41-48.
[3] SPRANGER S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol, 2016, 28(8):383-391.
[4] SHARMA P, HU-LIESKOVAN S, WARGO J A, et al. Primary, adaptive, and acquired resistance to cancer immunother. Cell, 2017, 168(4):707-723.
[5] REKHA M R, SHARMA C P. Oral delivery of therapeutic protein/peptide for diabetes-future perspectives. Int J Pharm, 2013, 440(1):48-62.
[6] LANITIS E, IRVING M, COUKOS G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol, 2015, 33: 55-63.
[7] CORZO C A, CONDAMINE T, LU L, et al. HIF-1 alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med, 2010, 207(11):2439-2453.
[8] QIAN B Z, POLLARD J W. Macrophage diversity enhances tumor progression and metastasis. Cell, 2010, 141(1):39-51.
[9] GABRILOVICH D I, OSTRAND-ROSENBERG S, BRONTE V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol, 2012, 12(4):253-268.
[10] CURIEL T J, COUKOS G, ZOU L H, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004, 10(9):942-949.
[11] BUCALA R, RITCHLIN C, WINCHESTER R, et al. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med, 1991, 173(3):569-574.
[12] SEIBERT K, MASFERRER J L. Role of inducible cyclooxygenase (Cox-2) in inflammation. Receptor, 1994, 4(1):17-23.
[13] BAGGIOLINI M. Chemokines and leukocyte traffic. Nature, 1998, 392(6676):565-568.
[14] ZARIF J C, TAICHMAN R S, PIENTA K J. TAM Macrophages promote growth and metastasis within the cancer ecosystem. Oncoimmunol, 2014, 3(7):e94173.
[15] MUSETTI S, HUANG L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy. Acs Nano, 2018, 12(12):11740-11755.
[16] LIU Y, CAO X T. The origin and function of tumor-associated macrophages. Cell Mol Immunol, 2015, 12(1):1-4.
[17] CARMELIET P, JAIN R K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801):249-257.
[18] SHWEIKI D, ITIN A, SOFFER D, et al. Vascular endothelial growth-factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359(6398):843-845.
[19] KOUREMBANAS S, HANNAN R L, FALLER D V. Oxygen-tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial-cells. J Clin Invest, 1990, 86(2):670-674.
[20] NOY R, POLLARD J W. Tumor-associated macrophages: from mechanisms to therapy. Immunity, 2014, 41(1):49-61.
[21] ALDERTON G K. Turning macrophages on, off and on again. Nat Rev Immunol, 2014, 14(3):136-137.
[22] SHANG B, LIU Y, JIANG S J, et al. Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers: a systematic review and Meta-analysis. Sci Rep-Uk, 2015, 5: 15179.
[23] KIM B Y S, RUTKA J T, CHAN W C W. Current concepts: nanomedicine. New Engl J Med, 2010, 363(25):2434-2443.
[24] CHO K J, WANG X, NIE S M, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res, 2008, 14(5):1310-1316.
[25] ZAMBONI W C, TORCHILIN V, PATRI A K, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res, 2012, 18(12):3229-3241.
[26] BULBAKE U, DOPPALAPUDI S, KOMMINENI N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics, 2017, 9(2):12.
[27] HODI F S, O′DAY S J, MCDERMOTT D F, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med, 2010, 363(8):711-723.
[28] SYN N L, TENG M W L, MOK T S K, et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol, 2017, 18(12):731-741.
[29] KWAK G, KIM D, NAM G H, et al. Programmed cell death protein ligand-1 silencing with polyethylenimine-dermatan sulfate complex for dual inhibition of melanoma growth. Acs Nano, 2017, 11(10):10135-10146.
[30] PRUITT S K, BOCZKOWSKI D, DE ROSA N, et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol, 2011, 41(12):3553-3563.
[31] GOODWIN T J, SHEN L M, HU M Y, et al. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials, 2017, 141: 260-271.
[32] CHRISTIAN D A, HUNTER C A. Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy-Uk, 2012, 4(4):425-441.
[33] KLEINERMAN E S, SCHROIT A J, FOGLER W E, et al. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest, 1983, 72(1):304-315.
[34] SMYTH M J, TENG M W L, SWANN J, et al. CD4(+)-CD25(+) T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol, 2006, 176(3):1582-1587.
[35] WRZESINSKI S H, WAN Y S Y, FLAVELL R A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res, 2007, 13(18):5262-5270.
[36] LIU V C, WONG L Y, JANG T, et al. Tumor evasion of the immune system by converting CD4(+) CD25(-) T cells into CD4(+) CD25(+) T regulatory cells: role of tumor-derived TGF-beta. J Immunol, 2007, 178(5):2883-2892.
[37] XU Z H, WANG Y H, ZHANG L, et al. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. Acs Nano, 2014, 8(4):3636-3645.
[38] HOLTZHAUSEN A, ZHAO F, EVANS K S, et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res, 2015, 3(9):1082-1095.
[39] PIERSMA B, BANK R A, BOERSEMA M. Signaling in fibrosis: TGF-beta, WNT, and YAP/TAZ converge. Front Med (Lausanne), 2015, 2: 59.
[40] LIU Q, ZHU H, TIRUTHANI K, et al. Nanoparticle-mediated trapping of Wnt family member 5A in tumor microenvironments enhances immunotherapy for B-Raf proto-oncogene mutant melanoma. Acs Nano, 2018, 12(2):1250-1261.
[41] ZHU S J, NIU M M, O′MARY H, et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm, 2013, 10(9):3525-3530.
[42] KAKOSCHKY B, PLELI T, SCHMITHALS C, et al. Selective targeting of tumor associated macrophages in different tumor models. PLoS One, 2018, 13(2):e0193015.
[43] CHOO Y W, KANG M, KIM H Y, et al. M1 Macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. Acs Nano, 2018, 12(9):8977-8993.
[44] ROSENBERG S A, YANG J C, RESTIFO N P. Cancer immunotherapy: moving beyond current vaccines. Nat Med, 2004, 10(9):909-915.
[45] MOCELLIN S, MANDRUZZATO S, BRONTE V, et al. Part I: vaccines for solid tumours. Lancet Oncol, 2004, 5(11):681-689.
[46] MELLMAN I, COUKOS G, DRANOFF G. Cancer immunotherapy comes of age. Nature, 2011, 480(7378):480-489.
[47] SHAHBAZI M A, SANTOS H A. Revolutionary impact of nanovaccines on immunotherapy. New Horiz Transl Med, 2015, 2(2):44-50.
[48] HENRIKSEN-LACEY M, KORSHOLM K S, ANDERSEN P, et al. Liposomal vaccine delivery systems. Expert Opin Drug Del, 2011, 8(4):505-519.
[49] TORRES M P, WILSON-WELDER J H, LOPAC S K, et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater, 2011, 7(7):2857-2864.
[50] KLINMAN D M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol, 2004, 4(4):249-258.
[51] LYNN G M, LAGA R, DARRAH P A, et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol, 2015, 33(11):1201-1210.
[52] ZHANG Z P, TONGCHUSAK S, MIZUKAMI Y, et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials, 2011, 32(14):3666-3678.
[53] HU X M, WU T T, QIN X Y, et al. Tumor lysate-loaded lipid hybrid nanovaccine collaborated with an immune checkpoint antagonist for combination immunotherapy. Adv Healthc Mater, 2019, 8(1):1800837.
[54] KUAI R, OCHYL L J, BAHJAT K S, et al. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater, 2017, 16(4):489-496.
[55] KEPP O, SENOVILLA L, KROEMER G. Immunogenic cell death inducers as anticancer agents. Oncotarget, 2014, 5(14):5190-5191.
[56] LIU Q, CHEN F, HOU L, et al. Nanocarrier-mediated chemo-immunotherapy arrested cancer progression and induced tumor dormancy in desmoplastic melanoma. Acs Nano, 2018, 12(8):7812-7825.
[57] ADKINS I, FUCIKOVA J, GARG A D, et al. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology, 2014, 3(12):e968434.
[58] MITSUNAGA M, OGAWA M, KOSAKA N, et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med, 2011, 17(12):1685-1691.
[59] MAZZIERI R, PUCCI F, MOI D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell, 2011, 19(4):512-526.
[60] SUN L, LIU Y J, YANG Z Z, et al. Tumor specific delivery with redox-triggered mesoporous silica nanoparticles inducing neovascularization suppression and vascular normalization. Rsc Adv, 2015, 5(68):55566-55578.
[61] DU S, XIONG H, XU C, et al. Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines. Biomater Sci, 2019, 7(3):1147-1160.
[62] LI W, LI X, LIU S, et al. Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition. Int J Nanomed, 2017, 12: 3509-3520.
[63] HU C H, LIU X Y, RAN W, et al. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials, 2017, 144: 60-72.
[64] HAN X X, LI Y Y, XU Y, et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nat Commun, 2018, 9: 3390.
[65] ZHAO J, XIAO Z, LI T, et al. Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer. Acs Nano, 2018, 12(10):9881-9893.